Upperton Pharma Solutions Names Michael Mellor-Clark as Chief Commercial Officer

• Upperton Pharma Solutions has appointed Michael Mellor-Clark as Chief Commercial Officer as it completes its new sterile manufacturing facility.

• Mellor-Clark brings over 25 years of international commercial leadership experience to support the company’s continued CDMO expansion.

Upperton Pharma Solutions has appointed Michael Mellor-Clark as its new Chief Commercial Officer (CCO), marking a strategic addition to the leadership team during a period of expansion into sterile manufacturing and commercial production in the EU and US.

The appointment follows the build of the company’s new 60,000 sq. ft sterile manufacturing facility in Nottingham, designed to support its integrated contract manufacturing services across oral, liquid, semi-solid, inhalation, and sterile dosage forms. As a UK-based CDMO, Upperton provides end-to-end solutions from pre-clinical development to market supply.

Michael Mellor-Clark brings more than 25 years of international experience in commercial operations and business development, having held senior positions at Concept Life Sciences, PathoQuest, and BioReliance (Merck KGaA). In his new role, he will guide Upperton’s commercial strategy and contribute to expanding its presence across key global markets.

“I am delighted to be joining Upperton at such a pivotal time in their history,” Mellor-Clark said. “Being part of the continued growth and leading the commercial aims is an exciting role, and I’m pleased to be part of a great team that puts clients and patients at the heart of everything they do.”

Upperton was recently recognised as the Champion Winner of the Small Molecule Dosage Form International category at the CDMO Leadership Awards 2025, underscoring its growing prominence in the contract manufacturing sector.